Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Trading 08-20 10:15:03 EDT

15.06

-0.71

-4.53%

High15.90	Low14.83	Vol67.83K
Open15.52	D1 Closing15.77	Amplitude6.78%
Mkt Cap1.28B	Tradable Cap820.14M	Total Shares85.31M
T/O1.03M	T/O Rate0.12%	Tradable Shares54.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":15.055,"timestamp":1787235300974,"preClose":15.77,"halted":0,"volume":67832,"delay":0,"changeRate":-0.045339251743817366,"floatShares":54476100,"shares":85313401,"eps":-1.744998,"marketStatus":"Trading","change":-0.715,"latestTime":"08-20 10:15:03 EDT","open":15.52,"high":15.9,"low":14.83,"amount":1031677.169768,"amplitude":0.06785,"askPrice":15.1,"askSize":27,"bidPrice":15.03,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.744998,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787256000000},"marketStatusCode":2,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":15.77,"preHourTrading":{"tag":"盘前","latestPrice":15.91,"preClose":15.77,"latestTime":"09:28 EDT","volume":628,"amount":9920.290547999999,"timestamp":1787232480104,"change":0.14,"changeRate":0.008878,"amplitude":0.084971},"postHourTrading":{"tag":"盘后","latestPrice":15.77,"preClose":15.77,"latestTime":"19:32 EDT","volume":14844,"amount":234050.12,"timestamp":1787182365878,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.683028,"impliedVol":1.4478,"impliedVolPercentile":0.9124},"requestUrl":"/m/hq/s/GLUE/wiki","defaultTab":"wiki","newsList":[{"id":"2660170137","title":"Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170137","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660170137?lang=en_us&edition=fundamental","pubTime":"2026-08-17 00:23","pubTimestamp":1786897401,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. reported past earnings for the second quarter and first half of 2026, with net loss widening to US$43.4 million for the quarter and US$87.9 million for the six-month period, alongside basic and diluted loss per share of US$0.43 and US$0.87 respectively from continuing operations.\nAn important insight is the swing from prior-year profitability over the first half of the year to a loss, marking a clear shift in the company’s recent financial profile.\nWe will now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/widening-losses-and-profitability-swing-might-change-the-cas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/widening-losses-and-profitability-swing-might-change-the-cas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315159","title":"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:10","pubTimestamp":1786619422,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monte Rosa Therapeutics (GLUE), Mineralys Therapeuti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-mineralys-therapeutics-inc-mlys-and-adagene-adag-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-mineralys-therapeutics-inc-mlys-and-adagene-adag-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XLV","BK4581","GLUE","MLYS","LU0128526141.USD","BK4539","BK4585","LABU","HCSG","BK4137","ADAG","BK4588","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657464160","title":"Monte Rosa Therapeutics is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657464160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657464160?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:56","pubTimestamp":1786110960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610434","title":"Gyre Therapeutics Q2 Revenue Beats Estimates on Higher Etuary Sales Volumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610434","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610434?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:13","pubTimestamp":1786101215,"startTime":"0","endTime":"0","summary":"Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumesOverviewUS-China biopharma firm's Q2 revenue fell yr/yr but beat analyst expectationsCompany reported Q2 GAAP net loss widene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","BK4139","LU0203347892.USD","LU0472753341.HKD","ZNTL","LU0689626769.HKD","LU0203345920.USD","BK4588","GYRE","LU0124676726.USD","LU0069063385.USD","LU0154245673.USD","BK4533","LU0154245756.USD","MADE","BK4585","LU2463526074.USD","BK4539","BK4149","LU0057025933.USD","LU0289961442.SGD","GLUE","LU0511384066.AUD","CMI","IE000M9KFDE8.USD","LU0289739343.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668017","title":"Relay Therapeutics Q2 Revenue Misses Estimates on Higher R&D Expenses; Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668017","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668017?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:40","pubTimestamp":1786048849,"startTime":"0","endTime":"0","summary":"Relay Therapeutics Q2 revenue misses estimates on higher R&D expenses; net loss widensOverviewUS precision medicine developer's Q2 revenue declined and missed analyst expectationsNet loss for Q2 widen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4539","RLAY","BK4563","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657630275","title":"Monte Rosa Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657630275","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657630275?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:32","pubTimestamp":1786026758,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryMonte Rosa Therapeutics, Inc.GLUE.OQreported a quarterly adjusted loss of 43 cents per share for the quart","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635472","title":"Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635472","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635472?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:42","pubTimestamp":1786016579,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over losses of $(0.15) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60990131/monte-rosa-therapeutics-q2-eps-0-43-misses-0-38-estimate-sales-8-968m-beat-5-524m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633979","title":"Monte Rosa Publishes Corporate Presentation on Targeted Protein Degradation Pipeline and Molecular Glue Degraders","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633979?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:25","pubTimestamp":1786015513,"startTime":"0","endTime":"0","summary":"Monte Rosa publishes corporate presentation on targeted protein degradation pipeline and molecular glue degradersMonte Rosa highlighted three clinical molecular glue degrader programs with Phase 2 tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6bK8Pf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633620","title":"Monte Rosa Activates Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633620?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:23","pubTimestamp":1786015386,"startTime":"0","endTime":"0","summary":"Monte Rosa activates Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in metastatic prostate cancerMonte Rosa Therapeutics completed enrollment and dosing in its GFORCE-1 Phase 1 study of MRT-810","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL4Q46sB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638713","title":"Monte Rosa Q2 FY26 Net Loss Widens to $43.4 Million; Revenue Falls 61.3% to $9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638713","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638713?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:14","pubTimestamp":1786014874,"startTime":"0","endTime":"0","summary":"Monte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 millionMonte Rosa Therapeutics posted a net loss of $43.4 million in Q2 2026, widening from a $12.3 million loss a year e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL2pKP5V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657368043","title":"Monte Rosa Therapeutics Q2 Operating Expenses USD 58.098 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657368043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657368043?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXX9Z77D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568321","title":"Monte Rosa’s MODeFIRe-1 Trial Pushes GLUE Into a Key Mid-Stage Prostate Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568321","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568321?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:31","pubTimestamp":1785861074,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. ($GLUE) announced an update on their ongoing clinical study. Monte Rosa Therapeutics, Inc. is running a Phase 2 study...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/monte-rosas-modefire-1-trial-pushes-glue-into-a-key-mid-stage-prostate-cancer-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/monte-rosas-modefire-1-trial-pushes-glue-into-a-key-mid-stage-prostate-cancer-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656746413","title":"Monte Rosa Therapeutics is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2656746413","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656746413?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:29","pubTimestamp":1785763740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656395746","title":"Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2656395746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656395746?lang=en_us&edition=fundamental","pubTime":"2026-08-01 02:50","pubTimestamp":1785523843,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) is trading lower after Novo Nordisk’s (NVO) ZEUS trial failed to show a cardiovascular benefit for IL 6 inhibition, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-bioage-sink-following-novo-nordisks-zeus-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-bioage-sink-following-novo-nordisks-zeus-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU1093756168.USD","BK4585","IE00BKVL7J92.USD","NVOX","BK4599","NVOH","LU0154236417.USD","BK4139","BK4007","THNR","BK4539","BIOA","BK4588","OZEM","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVO","PPH","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539514","title":"Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656539514?lang=en_us&edition=fundamental","pubTime":"2026-08-01 02:35","pubTimestamp":1785522928,"startTime":"0","endTime":"0","summary":"Jefferies lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $25 from $40 and keeps a Buy rating on the shares after Novo Nordisk...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-price-target-lowered-at-jefferies-after-novo-trial-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-price-target-lowered-at-jefferies-after-novo-trial-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655767367","title":"Monte Rosa Tumbles on Read-through from Novo's Cardiovascular Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2655767367","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655767367?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:05","pubTimestamp":1785510350,"startTime":"0","endTime":"0","summary":"BUZZ-Monte Rosa tumbles on read-through from Novo's cardiovascular trial failure** Shares of Monte Rosa TherapeuticsGLUE.Ofall 31.5% to four-month low of $15.54** Novo Nordisk'sNOVOb.COsays its experi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4N43X1U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655367139","title":"Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2655367139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655367139?lang=en_us&edition=fundamental","pubTime":"2026-07-31 22:39","pubTimestamp":1785508752,"startTime":"0","endTime":"0","summary":"Price: 15.68, Change: -7.00, Percent Change: -30.86","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652521806","title":"Have Insiders Sold Monte Rosa Therapeutics Shares Recently?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652521806","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652521806?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:30","pubTimestamp":1784543430,"startTime":"0","endTime":"0","summary":"Anyone interested in Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) should probably be aware that the President, Markus...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/have-insiders-sold-monte-rosa-therapeutics-shares-recently","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/have-insiders-sold-monte-rosa-therapeutics-shares-recently","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652280447","title":"Monte Rosa CEO Markus Warmuth Sells 9,500 Shares Worth $220,219.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2652280447","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652280447?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:05","pubTimestamp":1784318748,"startTime":"0","endTime":"0","summary":"Monte Rosa CEO Markus Warmuth sells 9,500 shares worth $220,219.55Monte Rosa Therapeutics President and CEO Markus Warmuth sold 9,500 common shares on July 16, 2026.Shares were sold at a weighted aver","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL4sNbnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa CEO Markus Warmuth Sells 9,500 Shares Worth $220,219.55","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652247324","title":"Monte Rosa COO Jennifer Champoux Disposes of 4,351 Common Shares Worth $101,707.28","url":"https://stock-news.laohu8.com/highlight/detail?id=2652247324","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652247324?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:11","pubTimestamp":1784232687,"startTime":"0","endTime":"0","summary":"Monte Rosa COO Jennifer Champoux disposes of 4,351 common shares worth $101,707.28Monte Rosa Therapeutics COO Jennifer Champoux sold 4,351 common shares on July 15, 2026 at USD 23.38.She also exercise","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL1SvgmC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Monte Rosa COO Jennifer Champoux Disposes of 4,351 Common Shares Worth $101,707.28","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":-0.3284},{"period":"3month","weight":-0.1647},{"period":"6month","weight":-0.1691},{"period":"1year","weight":2.5841},{"period":"ytd","weight":0.0057}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.4,"avgChangeRate":0.028615},{"month":4,"riseRate":0.4,"avgChangeRate":-0.132561},{"month":5,"riseRate":0.4,"avgChangeRate":-0.001871},{"month":6,"riseRate":0.6,"avgChangeRate":0.078411},{"month":7,"riseRate":0.666667,"avgChangeRate":0.006501},{"month":8,"riseRate":0.333333,"avgChangeRate":0.074727},{"month":9,"riseRate":0.4,"avgChangeRate":-0.025082},{"month":10,"riseRate":0.8,"avgChangeRate":0.245263},{"month":11,"riseRate":0.4,"avgChangeRate":0.027512},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction